Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6661 to 6675 of 8900 results

  1. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development Reference number: GID-TA10899 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  7. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development Reference number: GID-TA11044 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development Reference number: GID-TA11344 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development Reference number: GID-TA11401 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-TA11569 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued Reference number: GID-TA11522

    Technology appraisal guidance
    Discontinued

  12. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  13. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  14. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  15. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued